Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin
C Lanvers-Kaminsky, G Ciarimboli - Pharmacogenomics, 2017 - Future Medicine
Aminoglycosides and the anticancer drug cisplatin can cause permanent hearing loss,
which impacts patients' quality of life and results in considerable subsequent costs. Since …
which impacts patients' quality of life and results in considerable subsequent costs. Since …
Polymorphic Variation in TPMT Is the Principal Determinant of TPMT Phenotype: A Meta‐Analysis of Three Genome‐Wide Association Studies
Thiopurine‐related hematotoxicity in pediatric acute lymphoblastic leukemia (ALL) and
inflammatory bowel diseases has been linked to genetically defined variability in thiopurine …
inflammatory bowel diseases has been linked to genetically defined variability in thiopurine …
[HTML][HTML] Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families
MC Pouliot, C Kothari, C Joly-Beauparlant, Y Labrie… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Approximately 25% of hereditary breast cancer cases are associated with a strong familial
history which can be explained by mutations in BRCA1 or BRCA2 and other lower …
history which can be explained by mutations in BRCA1 or BRCA2 and other lower …
Methods to analyze big data in pharmacogenomics research
The scale and scope of pharmacogenomics research continues to expand as the cost and
efficiency of molecular data generation techniques advance. These new technologies give …
efficiency of molecular data generation techniques advance. These new technologies give …
DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors
Background Ototoxicity is a common adverse side effect of platinum chemotherapy and
cranial radiation therapy; however, individual susceptibility is highly variable. Therefore, our …
cranial radiation therapy; however, individual susceptibility is highly variable. Therefore, our …
Rethinking ovarian cancer genomics: where genome-wide association studies stand?
R Pinto, J Assis, A Nogueira, C Pereira… - …, 2017 - Future Medicine
Genome-wide association studies (GWAS) allow the finding of genetic variants associated
with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since …
with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since …
医学大数据在药物基因组学领域中的应用与发展
孙可欣, 詹思延, 胡永华 - 药物流行病学杂志, 2017 - cqvip.com
随着药物基因组学研究的不断发展, 医学大数据在药物基因组学领域中的应用越来越多.
本文从建立大型药物基因组学数据库, 借助电子健康档案与基因分型数据库开展药物基因组学 …
本文从建立大型药物基因组学数据库, 借助电子健康档案与基因分型数据库开展药物基因组学 …
[HTML][HTML] 表达数量性状位点分析在药物基因组学中的应用
陈长仁, 何发忠, 刘谋泽, 周宏灏, 张伟 - 药学学报, 2017 - html.rhhz.net
在全基因组关联分析(GWAS) 时代发现的大量药物应答相关位点位于非编码序列,
对其机制解释多关注于这些位点对mRNA 表达水平的影响. 表达数量性状位点(expression …
对其机制解释多关注于这些位点对mRNA 表达水平的影响. 表达数量性状位点(expression …
Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma …
Objective: To examine germline single nucleotide polymorphisms (SNPs) as markers of
response to gemcitabine platinum (GP) combination chemotherapy in urothelial carcinoma …
response to gemcitabine platinum (GP) combination chemotherapy in urothelial carcinoma …
[PDF][PDF] Genome-wide association studies and clinical outcome in ovarian cancer patients: validation in an independent cohort
RJC Pinto - 2017 - repositorio-aberto.up.pt
Durante esta etapa da minha vida académica que agora termina, tive a oportunidade de
alargar os meus conhecimentos numa área de eleição, assim como de crescer a nível …
alargar os meus conhecimentos numa área de eleição, assim como de crescer a nível …